Pfizer’s New Obesity Data Leaves Investors Wanting More

Pfizer Inc. revealed data from one of its new obesity treatments early Tuesday with little detail, leaving investors wondering if the up to $10 billion it spent purchasing the company that created the medicine will pay off.

The drugmaker battled to buy weight-loss startup Metsera Inc. late last year. With no new drug approvals expected in 2026 and declining demand for Pfizer’s Covid products, investors have put their hopes on the success of Metsera’s experimental medications.